In first of its kind study, Prime Therapeutics explores paroxysmal nocturnal hemoglobinuria (PNH) C5 inhibitor treatment rates
EAGAN, Minn., Oct. 14, 2021 /PRNewswire/ --Leading pharmacy benefit manager (PBM) Prime Therapeutics LLC (Prime) used its integrated medical and pharmacy claims data to evaluate paroxysmal nocturnal hemoglobinuria (PNH) C5 inhibitor treatment rates among its commercially insured population.
- EAGAN, Minn., Oct. 14, 2021 /PRNewswire/ --Leading pharmacy benefit manager (PBM) Prime Therapeutics LLC (Prime) used its integrated medical and pharmacy claims data to evaluate paroxysmal nocturnal hemoglobinuria (PNH) C5 inhibitor treatment rates among its commercially insured population.
- "To our knowledge, this is the first real-world claims based PNH C5 inhibitor treatment assessment conducted by a PBM.
- Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry.
- Prime Therapeutics LLC (Prime) helps people get the medicine they need to feel better and live well.